(Q64140189)

English

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial. (English)

0 references

medical condition

chronic idiopathic myelofibrosis

0 references

0 references

0 references

0 references

April 2015

0 references

end time

December 2016

0 references

number of participants

39

0 references

clinical trial phase

phase II clinical trial

0 references

research site

Aarau cantonal Hospital

0 references

Hopitaux universitaires de Genève (HUG), Archives centrales

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

stated in

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14

0 references

Identifiers

ClinicalTrials.gov ID

NCT02311569

0 references

(Q64140189)

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)